Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA Talks: FDA Reminds Industry The Program Is Generic-Only

Executive Summary

Generic drug user fee negotiations began with a reminder that components of the program will not apply to other regulated drug sectors.

You may also be interested in...

GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table

Generic user fees could be segmented further by addition of new group.

Generic User Fees Would Create 10-Month ANDA Review Time

Annual revenue of $250 million to $300 million in generic drug user fees is discussed as FDA unveils its "four walls and a roof" guiding principles.

Generic User Fees Get Another Hearing As FDA Seeks More Public Comment

The agency may not feel all industry sector voices have been heard and wants to provide another opportunity for input at the May 10 session, but negotiations with GPhA and API groups are continuing.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts